262 unknown. 262 Phase 3, 87 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 262 | Unknown 262 |
| Phase 2 | 87 | Unknown 87 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), control group - COVID-19 | Phase 3 | Unknown | WestVac Biopharma Co., Ltd. | 4950 | 2024-12-30 | 2024-07-25 |
| Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial Hyperbaric oxygen - Post-COVID-19 Syndrome, Post-COVID Syndrome | Phase 3 | Unknown | Erasmus Medical Center | 120 | 2024-10-01 | 2024-02-28 |
| Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia. TAD® 600 mg/4 mL powder and solvent for solution for injection, Saline solution 0.9% of sodium chloride - Pneumonia, Myocardial Injury | Phase 3 | Unknown | Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica | 178 | 2024-06-25 | 2024-11-27 |
| Effect of Metformin in Reducing Fatigue in Long COVID in Adolescents Metformin, Placebo - Long COVID | Phase 3 | Unknown | Purpose Life Sciences | 16 | 2024-04-01 | 2024-03-04 |
| Stellate Ganglion Block With Lidocaine for the Treatment of COVID-19-Induced Parosmia Stellate Ganglion Block, Placebo - Parosmia | Phase 3 | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 44 | 2024-02-15 | 2024-10-23 |
| A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell), Recombinant COVID-19 Variant Vaccine (Sf9 Cell), Placebo - COVID-19 | Phase 3 | Unknown | WestVac Biopharma Co., Ltd. | 4800 | 2023-12-19 | 2024-04-23 |
| Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like Disease Formosa 1-Breath Free (NRICM101), Placebo control drug - Influenza Viral Infections, COVID-19 | Phase 3 | Unknown | China Medical University Hospital | 170 | 2023-12-15 | 2023-12-19 |
| IMMUNERECOV CONTRIBUTES TO IMPROVEMENT OF RESPIRATORY AND IMMUNOLOGICAL RESPONSE IN POST-COVID-19 PATIENTS. Nutritional blend (ImmuneRecov). - Long Covid19, Dietary Supplements | Phase 3 | Unknown | Federal University of São Paulo | 58 | 2023-12-10 | 2023-12-12 |
| Study of the Vector Vaccine GamCovidVac-M (Altered Antigenic Composition) GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition - COVID-19 | Phase 3 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 50 | 2023-10-01 | 2023-10-05 |
| Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Participation of Adult Volunteers GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) - COVID-19 | Phase 3 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 50 | 2023-10-01 | 2023-10-05 |
| Study of "Sputnik Lite" for the Prevention of COVID-19 With Altered Antigenic Composition. "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition - COVID-19 | Phase 3 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 50 | 2023-09-01 | 2023-09-28 |
| Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain, COVID-19 Vaccine (Vero Cell), Inactivated - COVID-19 | Phase 3 | Unknown | Sinovac Biotech (Colombia) S.A.S. | 1400 | 2023-08-10 | 2023-01-12 |
| "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype. Baricitinib 4 MG - Hospital-acquired Pneumonia | Phase 2 / Phase 3 | Unknown | Nantes University Hospital | 450 | 2023-07-01 | 2023-06-22 |
| INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg - COVID-19 Pandemic, COVID-19 Vaccines | Phase 3 | Unknown | Dr. Soetomo General Hospital | 400 | 2023-06-19 | 2024-02-28 |
| Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech), VidPrevtyn® Beta vaccine (Sanofi/GSK) - Vaccine Reaction, COVID-19 | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 248 | 2023-05-16 | 2023-06-29 |
| Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities Ropeginterferon alfa-2b, SOC - COVID-19 | Phase 2 / Phase 3 | Unknown | National Taiwan University Hospital | 60 | 2023-05-15 | 2023-04-11 |
| Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19 SHEN26 capsule, SHEN26 placebo - COVID-19 | Phase 3 | Unknown | Shenzhen Kexing Pharmaceutical Co., Ltd. | 1200 | 2023-05-13 | 2023-06-22 |
| Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes. SCB-2019/Clover, AstraZeneca/Fiocruz, Pfizer/Wyeth - COVID-19 | Phase 3 | Unknown | D'Or Institute for Research and Education | 760 | 2023-03-14 | 2023-04-13 |
| A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19 QLS1128, Placebo - COVID-19 | Phase 3 | Unknown | Qilu Pharmaceutical Co., Ltd. | 1220 | 2023-03-07 | 2023-03-10 |
| Early Treatment Strategy With High-dose Dexamethasone in Patients With SARS-CoV-2 Dexamethasone - Covid19, Dexamethasone | Phase 3 | Unknown | Hospital Universitario Infanta Leonor | 200 | 2023-02-28 | 2023-03-01 |
Showing 20 of 262. Sign in to see all of them.
COVID-19 (234) · Coronavirus Infections (27) · Severe Acute Respiratory Syndrome (12) · Cytokine Release Syndrome (8) · Pneumonia, Ventilator-Associated (8) · Pneumonia, Viral (6) · Post-Acute COVID-19 Syndrome (5) · Respiratory Tract Infections (5) · Healthcare-Associated Pneumonia (4) · Inflammation (4) · Respiratory Distress Syndrome (4) · Community-Acquired Pneumonia (3) · Pneumonia, Pneumocystis (3) · Virus Diseases (3)
Respiratory Tract Diseases (261) · Infections (260) · Lung Diseases (260) · Respiratory Tract Infections (257) · Coronaviridae Infections (238) · Nidovirales Infections (238) · RNA Virus Infections (237) · Virus Diseases (235) · Pneumonia, Viral (232) · Coronavirus Infections (211) · Pathologic Processes (34) · Pathological Conditions, Signs and Symptoms (34) · Disease Attributes (18) · Iatrogenic Disease (11)
Hydroxychloroquine (20) · Standard of Care (18) · Ivermectin (9) · favipiravir (9) · BNT162 Vaccine (7) · COVID-19 Vaccines (7) · Dexamethasone (7) · remdesivir (7) · Azithromycin (6) · Saline Solution (6) · COVID-19 Serotherapy (5) · Lopinavir (5) · Methylprednisolone (5) · Ritonavir (5) · nitazoxanide (5)
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (9) · Assistance Publique - Hôpitaux de Paris (6) · Cairo University (6) · Mansoura University (5) · Chinese Academy of Medical Sciences (4) · Tanta University (4) · Ain Shams University (3) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (3) · Genova Inc. (3) · London School of Hygiene and Tropical Medicine (3) · Sinocelltech Ltd. (3) · Azienda Ospedaliera Universitaria Integrata Verona (2) · Biomed Industries, Inc. (2) · Cadila Pharnmaceuticals (2) · Cambridge University Hospitals NHS Foundation Trust (2)
China (25) · Egypt (15) · Brazil (13) · Italy (13) · Russia (13) · France (12) · Indonesia (12) · United States (12) · Spain (10) · Pakistan (8) · Colombia (7) · Mexico (7) · Canada (6) · Philippines (6) · India (5)
Dominicus Husada, MD (2) · Lloyd Tran, PhD (2) · Yan Zheng (2) · Abdol Hossein Shahverdi (1) · Adilson JW Cavalcante, PhD (1) · Ahmad Faried, Prof. MD (1) · Ahmad Imran, MBBS (1) · Ahmed Cordie, lecturer (1) · Ahmed Rezk (1) · Ajay Gupta, MD (1) · Akter Kamal, MD, PhD (1) · Aleksandr Alekseevich Punin (1) · Aliae AR Mohamed-Hussein, MD (1)
PMID 34473343, PMID 35244208, PMID 37489818, PMID 32171076, PMID 34350582, PMID 36695483, PMID 25030060, PMID 32109013, PMID 32142651, PMID 33502773, PMID 36700518, PMID 41972135, PMID 10816031, PMID 10990547, PMID 11063978, PMID 11594901, PMID 11723286, PMID 12244081, PMID 12777656, PMID 12949224, PMID 14677403, PMID 15023839, PMID 15147306, PMID 15214887, PMID 15351385, PMID 15616839, PMID 15987799, PMID 16002441, PMID 16211552, PMID 16287208, PMID 16794566, PMID 17591596, PMID 17872488, PMID 18641114, PMID 19332318, PMID 19403329, PMID 19482956, PMID 19671217, PMID 19853048, PMID 20633386, PMID 20936977, PMID 21068312, PMID 21167786, PMID 21631313, PMID 21890211, PMID 22032743, PMID 22186217, PMID 22189047, PMID 22193671, PMID 22215866
2016 (1), 2018 (1), P30CA138292 (1)